Publication: Symptoms and impacts of nonsense mutation Duchenne muscular dystrophy at different stages of ambulation
This research article, published in Future Neurology, describes the symptoms of nonsense mutation Duchenne muscular dystrophy (nmDMD), and the impact of the condition on caregivers, at different stages of the disease
Read about the design of this study, which included qualitative interviews with 10 caregivers of UK patients with nmDMD
Review the results of the survey, evaluating the symptoms and impact of nmDMD at different stages of ambulatory decline, and assessing the health-related quality of life of those affected by nmDMD
Understand the burden that nmDMD places on both patients and their caregivers, in terms of daily and social activities, and emotional wellbeing
Williams K, Buesch K, Acaster S. Future Neurol. 2022. Online ahead of print
Once registered, you will be able to view the abstract and be provided the DOI and PubMed links for this publication.
▼ Ataluren is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to PTC at firstname.lastname@example.org.
Registration conditions differ internationally, and prescribing information may vary depending on local approval in each country. The European Summary of Product Characteristics for ataluren is available here. Please refer to your local country guidance for more information.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-DMD-2200118 | May 2022
Sign in or register to access exclusive content on this site